Overview: Mitochondrial Genome Sequencing TestIntroduction: The Mitochondrial Genome Sequencing Test sequences the mitochondrial genome to diagnose mitochondrial disorders, causing muscle weakness or seizures. Following 2023 UMDF guidelines, it uses PCR for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected mitochondrial diseases.
Other Names: Mitochondrial Seq Assay, mtDNA Sequencing Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Mitochondrial genome sequencing began in the 1990s with mitochondrial research. Sequencing methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Sequences mitochondrial genome to diagnose mitochondrial disorders, guides treatment, and evaluates patients with muscle weakness or seizures.
Test Parameters: 1. Mitochondrial Genome Sequence
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of muscle weakness, seizures, or mitochondrial symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document muscle weakness, seizures, ataxia, or family history of mitochondrial disorders. Include current medications, especially antiepileptics.
Consent: Written consent required, detailing the tests purpose, mitochondrial disorder implications, and risks of sample collection.
Procedural Considerations: Uses PCR and sequencing to analyze the mitochondrial genome in specimens. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for mitochondrial disorder diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm mitochondrial disorder, guiding supportive care or genetic counseling. Negative results may require nuclear DNA testing.
Specialist Consultation: Consult a neurologist or geneticist for result interpretation and treatment planning.
Additional Supporting Tests: Muscle biopsy, lactate levels, or EEG to confirm mitochondrial disorder diagnosis.
Test Limitations: Not all mitochondrial disorders are detected; clinical correlation is needed. Sample quality affects sensitivity.
References: UMDF Mitochondrial Guidelines, 2023; Neurology, DiMauro S, 2022.
